Gecko-Inspired Nanoparticles Show Promise for Targeted Bladder Cancer Therapy
核心洞察
CU Boulder (搜索) scientists developed gecko-inspired nanoparticles using FDA-approved PLGA (搜索) polymer that can stick to tumors and deliver sustained chemotherapy for days.
The particles successfully adhered to bladder tumors in mice for extended periods, even in the slippery bladder environment, while being well-tolerated and eliciting favorable immune responses.
This technology could potentially reduce treatment frequency for bladder cancer patients and minimize side effects by delivering high concentrations of drugs directly to tumors.
CU Boulder (搜索) scientists have developed gecko-inspired nanoparticles that can adhere to tumors and deliver sustained chemotherapy, potentially transforming treatment approaches for bladder cancer and other localized tumors. The technology, created in collaboration with doctors at the University of Colorado Anschutz Medical Campus, mimics the extraordinary adhesive properties of gecko feet to create a targeted drug delivery system.
Biomimetic Innovation Addresses Treatment Challenges
The research team, led by senior author Wyatt Shields, Thomas F. Austin assistant professor of Chemical and Biological Engineering at CU Boulder (搜索), drew inspiration from the millions of microscopic, hair-like fibers called setae that line gecko toes. These structures, along with thousands of even tinier split ends called spatulae, flatten across surfaces and conform to nooks and crannies, creating strong adhesion through Van der Waals forces.
"Nature has been at this for millions of years and offers clues for developing better biomaterials," Shields said.
The team developed a method to transform poly lactic-co-glycolic acid (PLGA (搜索)), an already FDA-approved biodegradable polymer, into small particles displaying branched hair-like nanostructures similar to those on gecko feet. These "soft dendritic particles" were then infused with chemotherapy drugs and tested on cancer cells and bladder tumors in mice.
Promising Preclinical Results
First-author Jin Gyun Lee, a postdoctoral researcher in the Shields Lab, reported encouraging early findings. The particles demonstrated the ability to cling tightly to cancer for days, even in the challenging environment of a bladder surface. The animals tolerated the treatment well and showed favorable immune responses.
"We've developed a practical, flexible platform for localized cancer therapy that could be easily scaled and translated," Lee said. "We envision that this gecko-inspired technology could ultimately reduce the frequency of clinical treatments, potentially allowing patients to receive fewer but longer-lasting therapies."
Addressing Bladder Cancer Treatment Limitations
The research specifically targets bladder cancer due to unique treatment challenges in this disease. Co-author Thomas Flaig, MD, an oncologist and professor of medicine at CU Anschutz who specializes in bladder cancer, explained the clinical need.
"Bladder cancer is common, with most patients presenting with localized disease," Flaig said. "There is a real need for new and effective therapies to prevent progression to more advanced stages of disease for these patients."
Current treatment for localized bladder tumors involves inserting a catheter and bathing the organ in chemotherapy drugs. However, because people urinate approximately six times daily, the medication washes out quickly, necessitating frequent repeat treatments that can be painful. Side effects are common as the drugs affect healthy tissue, and cancer recurrence remains a significant problem.
Future Applications and Development
The researchers envision applying a gel containing their gecko-inspired particles directly to tumors, delivering sustained, high concentrations of cancer-killing medicine more selectively until the particles break down and are excreted. The technology could potentially extend to other cancers, including oral, head, and neck tumors.
The authors emphasize that additional research is necessary, and clinical trials in humans could be years away. The team of biomedical and materials engineers, medical oncologists, and cancer biologists plans to continue their cross-campus collaboration while seeking further inspiration from nature for therapeutic innovations.